(Q37771015)

22 August 2017

1 reference

title

Current and future management options for myelodysplastic syndromes (English)

1 reference

22 August 2017

6

Hagop Kantarjian

1 reference

22 August 2017

2

Elias Jabbour

1 reference

22 August 2017

Guillermo Garcia-Manero

series ordinal

4

object named as

Guillermo Garcia-Manero

1 reference

22 August 2017

5

Jean-Pierre Issa

1 reference

22 August 2017

3

Hillary Prescott

1 reference

22 August 2017

1

Jeffrey Bryan

1 reference

22 August 2017

publication date

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

11

1 reference

22 August 2017

page(s)

1381-1394

1 reference

https://scigraph.springernature.com/pub.10.2165/11537920-000000000-00000

22 August 2017

exact match

0 references

cites work

Proposals for the classification of the myelodysplastic syndromes

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11537920-000000000-00000

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11537920-000000000-00000

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

21 January 2018

1 reference

12 December 2020

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

12 December 2020

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

12 December 2020

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Epidemiology of myelodysplastic syndromes

1 reference

12 December 2020

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

1 reference

12 December 2020

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

12 December 2020

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

1 reference

12 December 2020

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

12 December 2020

Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome

1 reference

12 December 2020

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

12 December 2020

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

1 reference

12 December 2020

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

1 reference

12 December 2020

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

12 December 2020

The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS).

1 reference

12 December 2020

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

12 December 2020

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

12 December 2020

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

1 reference

12 December 2020

The role of the immune system in myelodysplasia: implications for therapy

1 reference

12 December 2020

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

12 December 2020

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

1 reference

12 December 2020

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

12 December 2020

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

1 reference

12 December 2020

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

12 December 2020

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

12 December 2020

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

12 December 2020

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

1 reference

12 December 2020

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

1 reference

12 December 2020

The role of decitabine in the treatment of myelodysplastic syndromes

1 reference

12 December 2020

Novel therapies for myelodysplastic syndromes

1 reference

12 December 2020

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

1 reference

12 December 2020

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

1 reference

12 December 2020

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

12 December 2020

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes

1 reference

12 December 2020

Myelodysplastic syndromes--coping with ineffective hematopoiesis

1 reference

12 December 2020

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

12 December 2020

Disorders of iron metabolism

1 reference

12 December 2020

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

1 reference

12 December 2020

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

1 reference

12 December 2020

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

12 December 2020

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study

1 reference

12 December 2020

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

1 reference

12 December 2020

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

12 December 2020

Modifying the epigenome as a therapeutic strategy in myelodysplasia

1 reference

12 December 2020

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

12 December 2020

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

1 reference

12 December 2020

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

12 December 2020

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

1 reference

12 December 2020

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

1 reference

12 December 2020

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

1 reference

12 December 2020

Pathophysiology of iron overload.

1 reference

12 December 2020

Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients

1 reference

12 December 2020

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

12 December 2020

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

12 December 2020

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

12 December 2020

Survival and causes of death in thalassaemia major

1 reference

12 December 2020

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

12 December 2020

Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.

1 reference

12 December 2020

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

1 reference

12 December 2020

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

1 reference

12 December 2020

Acute myeloid leukemia and myelodysplastic syndromes in older patients

1 reference

12 December 2020

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes

1 reference

12 December 2020

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

12 December 2020

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

1 reference

12 December 2020

Consensus statement on iron overload in myelodysplastic syndromes

1 reference

12 December 2020

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

12 December 2020

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

1 reference

12 December 2020

10.2165/11537920-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1018918929

0 references

1 reference